# Tailored Operative or Non-operative Management for Low-risk Rectal Cancer After Intensive Neoadjuvant Treatment

> **NCT02860234** · — · COMPLETED · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 68 (actual)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **RADIATION:** intensity modulated radiotherapy
- **PROCEDURE:** DRE-Endoscopy-MRI-CEA
- **PROCEDURE:** Nonoperative Management
- **PROCEDURE:** Local Excision
- **PROCEDURE:** Total Mesorectal Excision
- **BEHAVIORAL:** Quality of Life Questionnaires

## Key facts

- **NCT ID:** NCT02860234
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2019-11
- **Final completion:** 2019-11
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2021-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02860234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02860234, "Tailored Operative or Non-operative Management for Low-risk Rectal Cancer After Intensive Neoadjuvant Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02860234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*